Hansa Biopharma AB (HNSBF)
2.93
0.00 (0.00%)
USD |
OTCM |
Sep 20, 16:00
Hansa Biopharma Enterprise Value: 222.22M for Sept. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
September 20, 2024 | 222.22M |
September 19, 2024 | 222.22M |
September 18, 2024 | 222.22M |
September 17, 2024 | 222.22M |
September 16, 2024 | 222.22M |
September 13, 2024 | 222.22M |
September 12, 2024 | 222.22M |
September 11, 2024 | 222.22M |
September 10, 2024 | 222.22M |
September 09, 2024 | 222.22M |
September 06, 2024 | 222.22M |
September 05, 2024 | 222.22M |
September 04, 2024 | 222.22M |
September 03, 2024 | 222.22M |
August 30, 2024 | 222.22M |
August 29, 2024 | 222.22M |
August 28, 2024 | 222.22M |
August 27, 2024 | 222.22M |
August 26, 2024 | 222.22M |
August 23, 2024 | 222.22M |
August 22, 2024 | 222.22M |
August 21, 2024 | 222.22M |
August 20, 2024 | 222.22M |
August 19, 2024 | 222.22M |
August 16, 2024 | 222.22M |
Date | Value |
---|---|
August 15, 2024 | 222.22M |
August 14, 2024 | 222.22M |
August 13, 2024 | 222.22M |
August 12, 2024 | 222.22M |
August 09, 2024 | 222.22M |
August 08, 2024 | 222.22M |
August 07, 2024 | 222.22M |
August 06, 2024 | 222.22M |
August 05, 2024 | 222.22M |
August 02, 2024 | 222.22M |
August 01, 2024 | 222.22M |
July 31, 2024 | 222.22M |
July 30, 2024 | 222.22M |
July 29, 2024 | 222.22M |
July 26, 2024 | 222.22M |
July 25, 2024 | 222.22M |
July 24, 2024 | 222.22M |
July 23, 2024 | 222.22M |
July 22, 2024 | 222.22M |
July 19, 2024 | 222.22M |
July 18, 2024 | 222.22M |
July 17, 2024 | 222.22M |
July 16, 2024 | 222.22M |
July 15, 2024 | 222.22M |
July 12, 2024 | 222.22M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
118.23M
Minimum
Dec 19 2023
1.231B
Maximum
Jul 27 2020
405.80M
Average
234.15M
Median
Apr 08 2022
Enterprise Value Benchmarks
Abliva AB | 11.86M |
Karolinska Development AB | 63.88M |
Calliditas Therapeutics AB | 1.098B |
Oncopeptides AB | -- |
BioInvent International AB | 209.26M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -19.49M |
Revenue (Quarterly) | 3.219M |
Total Expenses (Quarterly) | 20.79M |
EPS Diluted (Quarterly) | -0.3094 |
Gross Profit Margin (Quarterly) | -18.04% |
Profit Margin (Quarterly) | -605.6% |
Earnings Yield | -46.86% |
Normalized Earnings Yield | -46.86 |